Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate

This publication has 51 references indexed in Scilit:

• PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication
  Annual Review of Pharmacology and Toxicology, 2005
• Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
  Journal of Clinical Oncology, 2005
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• Mitochondrial-Mediated Disregulation of Ca2+ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines
  Cancer Research, 2005
• Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions
  Biochemical Journal, 2003
• The Caspase-like Sites of Proteasomes, Their Substrate Specificity, New Inhibitors and Substrates, and Allosteric Interactions with the Trypsin-like Sites
  Journal of Biological Chemistry, 2003
• Redundancy of Mammalian Proteasome β Subunit Function during Endoplasmic Reticulum Associated Degradation
  Biochemistry, 2001
• DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
  Annual Review of Immunology, 1999
• Kinetic Studies of the Branched Chain Amino Acid Preferring Peptidase Activity of the 20S Proteasome: Development of a Continuous Assay and Inhibition by Tripeptide Aldehydes and clasto-Lactacystin β-Lactone
  Biochemistry, 1998
• Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range
  Science, 1972